Acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia, chronic myelogenous leukaemia

Indication for 22-Oxovincaleukoblastine

Population group: Suitable for both men and women, only adults (18 years old or older)

Leukaemias, including acute lymphocytic leukaemia, chronic lymphocytic leukaemia, acute myelogenous leukaemia and blastic crisis of chronic myelogenous leukaemia.

For this indication, competent medicine agencies globally authorize below treatments:

1.4-1.5 mg/m² once weekly

Route of admnistration

Intravenous

Defined daily dose

1.4 - 1.5 mg per m² of body surface area (BSA)

Dosage regimen

From 1.4 To 1.5 mg per m² of body surface area (BSA) once every 7 day(s)

Detailed description

The drug is administered intravenously at weekly intervals. The recommended dose is 1.4 to 1.5 mg/m² up to a maximum weekly dose of 2 mg.

Active ingredient

Vincristine is an antineoplastic drug with broad-spectrum anti-tumor activity in man. The drug may act by mitotic inhibition, causing an arrest of cell division in metaphase.

Read more about 22-Oxovincaleukoblastine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner